Morgan Stanley Maintains Equal-Weight on Genmab, Raises Price Target to $57

Benzinga · 1d ago
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and raises the price target from $42 to $57.